IDNA — iShares Genomics Immunology and Healthcare ETF
Data updated: 2026-06-25
IDNA — iShares Genomics Immunology and Healthcare ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Global (incl. US) Health Care Equity · $160.48M AUM · 0.47% expense ratio · 41.5% 1-yr return. From SEC regulatory filings.
IDNA Fund Overview
IDNA — iShares Genomics Immunology and Healthcare ETF is a US ETF managed by iSHARES TRUST, categorised as Global (incl. US) Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: iSHARES TRUST
- Category: Global (incl. US) Health Care Equity
- Assets under management: $160.48M
- 1-year return: 41.5%
- Ticker: IDNA
- SEC CIK: 0001100663
- SEC series ID: S000065599
- Share class ID: C000212225
IDNA Holdings
Top 10 holdings of iShares Genomics Immunology and Healthcare ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 20.98% |
| Revolution Medicines, Inc. | 6.85% |
| Moderna, Inc. | 6.28% |
| Ipsen SA | 5.24% |
| Bayer Aktiengesellschaft | 4.38% |
| Takeda Pharmaceutical Company Limited | 4.22% |
| Merck & Co., Inc. | 4.15% |
| Gsk PLC | 4.12% |
| BioNTech SE | 4.07% |
| Roche Holding AG | 3.99% |
IDNA Portfolio Allocation
Asset-class allocation of iShares Genomics Immunology and Healthcare ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 95.1% |
| Cash & Equivalents | 21.0% |
| Other | 4.2% |
IDNA Performance
Total returns for IDNA (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 12.5% |
| 1 year | 41.5% |
| 3 years (annualised) | 9.0% |
| 5 years (annualised) | -8.5% |
IDNA Risk Information
Risk metrics for IDNA, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 19.4%
IDNA Costs and Fees
IDNA costs about $47 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.47%
- Gross expense ratio: 0.47%
- Portfolio turnover: 49%
- Brokerage commissions: 5.45 bps of average net assets (SEC N-CEN)
IDNA Cashflows
Over the 12 months to 2026-04, iShares Genomics Immunology and Healthcare ETF had net inflows of $7.50M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $7.71M |
| 2026-03 | $3.00M |
| 2026-02 | $3.09M |
| 2026-01 | $0 |
| 2025-12 | $4.03M |
| 2025-11 | −$5.18M |
IDNA Debt Constituents
No individual debt constituents are reported in iShares Genomics Immunology and Healthcare ETF's latest SEC N-PORT filing.
IDNA Prospectus and SEC Filings
Official iShares Genomics Immunology and Healthcare ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Global (incl. US) Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.